Bexotegrast (PLN-74809) is a potent, orally bioavailable dual inhibitor of alphavbeta6 and alphavbeta1 integrins that blocks TGF-beta activation. Its antifibrotic properties are being investigated in preclinical and clinical research for fibrotic lung diseases, including idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).